The Prostate, Lung, Cancer, and Ovarian Cancer Screening Trial is a randomized, multicenter, study evaluating whether screening for prostate, lung, colon, and ovarian cancer will reduce cancer-specific mortality. More than 155,000 participants have been identified and will be monitored through 2015. A biorepository of screened individuals and control participants has been created. Together, the data derived from the intervention and control arms and material in the biorepository provide a valuable resource to allow identification and testing of novel biomarkers for human disease.
Gerald L Andriole, Douglas Reding, Richard B Hayes, Philip C Prorok, John K Gohagan, and PLCO Steering Committee.
Division of Urologic Surgery, Washington University School of Medicine, Washington University in St. Louis, 4960 Children's Place, Campus Box 8242, St. Louis, MO 63110, USA. andrioleg@wustl.edu
Urol. Oncol. 2004 Jul 1;22(4):358-61.
AbstractThe Prostate, Lung, Cancer, and Ovarian Cancer Screening Trial is a randomized, multicenter, study evaluating whether screening for prostate, lung, colon, and ovarian cancer will reduce cancer-specific mortality. More than 155,000 participants have been identified and will be monitored through 2015. A biorepository of screened individuals and control participants has been created. Together, the data derived from the intervention and control arms and material in the biorepository provide a valuable resource to allow identification and testing of novel biomarkers for human disease.Copyright 2004 Elsevier Inc.